- A novel compound is found to enhance memory performance in animal models. However, at higher doses, it also causes involuntary, fine twitching of skeletal muscles. These dual effects suggest that the compound is likely an agonist or positive allosteric modulator of which receptor family?
Answer: Nicotinic receptors.
Nicotinic acetylcholine receptors are widely distributed in the central nervous system, where they play a key role in cognitive functions like learning and memory. They are also the sole acetylcholine receptor type at the neuromuscular junction (Nₘ subtype), where their stimulation leads to muscle contraction. A drug that enhances nicotinic receptor function could therefore plausibly enhance cognition (a CNS effect) and cause muscle fasciculations (a peripheral NMJ effect).
- A low intravenous dose of nicotine causes a transient decrease in heart rate. A subsequent higher dose causes a marked increase in heart rate and blood pressure. The initial bradycardia is best explained by stimulation of:
Answer: nicotinic Nₙ receptors in parasympathetic ganglia innervating the heart.
When you encounter questions about nicotine's cardiovascular effects, remember that nicotine acts on nicotinic receptors in both sympathetic and parasympathetic ganglia, but the dose determines which system dominates.
At low doses, nicotine primarily stimulates nicotinic Nₙ receptors in parasympathetic ganglia that innervate the heart. This enhances parasympathetic transmission, leading to increased acetylcholine release at the sinoatrial node. The acetylcholine then binds to muscarinic M2 receptors on the SA node, causing bradycardia. At higher doses, nicotine overwhelms parasympathetic effects by strongly stimulating sympathetic ganglia, resulting in tachycardia and hypertension.
Option A is incorrect because nicotine doesn't directly bind muscarinic M2 receptors—it's a nicotinic receptor agonist. The M2 receptors are stimulated by acetylcholine released from parasympathetic nerve terminals that nicotine activates upstream.
Option B describes what happens at higher doses, not the initial bradycardia. High-dose nicotine does stimulate sympathetic ganglia, but this explains the subsequent tachycardia and hypertension, not the initial heart rate decrease.
Option C is wrong because nicotine doesn't directly stimulate β1-adrenergic receptors. Any β1 stimulation would be indirect, occurring after nicotine activates sympathetic ganglia that release norepinephrine.
The correct answer is D—low-dose nicotine stimulates parasympathetic ganglia, enhancing vagal tone and causing bradycardia.
Study tip: Remember the dose-dependent biphasic response to nicotine: low doses favor parasympathetic effects (bradycardia), while high doses favor sympathetic effects (tachycardia). This pattern appears frequently on pharmacology exams.
- A patient taking varenicline for smoking cessation reports that cigarettes are no longer pleasurable. The patient also experiences mild nausea. Varenicline produces these effects by acting as a:
Answer: partial agonist at nicotinic α4β2 receptors in the CNS.
Varenicline is a partial agonist at the α4β2 subtype of nicotinic acetylcholine receptors in the brain's reward pathways. As a partial agonist, it provides moderate receptor stimulation to reduce cravings and withdrawal (which can also cause nausea). Simultaneously, it occupies the receptor, preventing nicotine (a full agonist) from binding effectively, thus blocking the rewarding effect of smoking.
- A patient is given a drug that causes miosis, bradycardia, and increased gastrointestinal motility. These effects are all blocked by atropine. However, the drug has no effect on skeletal muscle contraction or autonomic ganglia function. This drug is best classified as a:
Answer: selective muscarinic receptor agonist.
The described effects (miosis, bradycardia, GI motility) are all classic parasympathomimetic responses mediated by muscarinic receptors. The fact that they are blocked by atropine (a muscarinic antagonist) confirms this. The lack of effect on skeletal muscle (Nₘ receptors) or ganglia (Nₙ receptors) indicates that the drug does not act on nicotinic receptors. Therefore, it is a selective muscarinic receptor agonist (e.g., bethanechol). An AChE inhibitor or non-selective agonist would also have stimulated nicotinic receptors.
- A patient in the ICU is given succinylcholine for endotracheal intubation. A different patient on a urology ward is given bethanechol for urinary retention. Which of the following effects is characteristic of succinylcholine but NOT bethanechol?
Answer: Transient muscle fasciculations.
Succinylcholine is a depolarizing neuromuscular blocker that acts as an agonist at nicotinic Nₘ receptors at the neuromuscular junction. Its initial agonism causes disorganized muscle depolarization, seen as transient fasciculations, before paralysis ensues. Bethanechol is a selective muscarinic agonist and does not act on nicotinic receptors. The other options (miosis, increased secretions, bradycardia) are all classic muscarinic effects produced by bethanechol.
- What does this experiment demonstrate regarding the mechanism of sympathetic transmission?
Answer: Transmission through the sympathetic ganglion is mediated by nicotinic receptors.
The experiment shows that the signal from the preganglionic nerve is blocked by hexamethonium, a ganglionic (Nₙ) blocker. Since the postganglionic response to its own neurotransmitter (norepinephrine) is intact, the block must be at the ganglion. This demonstrates that the neurotransmission between the preganglionic and postganglionic neuron in the sympathetic ganglion requires the activation of nicotinic receptors by acetylcholine.
- An experimental drug is administered to a volunteer. The subject experiences sweating, salivation, and a sustained skeletal muscle contraction (tetany). Which statement best describes the pharmacological properties of this drug?
Answer: It is a long-acting acetylcholinesterase inhibitor.
The observed effects involve stimulation of both muscarinic and nicotinic systems. Sweating and salivation are mediated by muscarinic receptors. Sustained skeletal muscle contraction (tetany) results from intense stimulation of nicotinic Nₘ receptors at the neuromuscular junction. An acetylcholinesterase inhibitor would increase acetylcholine concentrations at both muscarinic and nicotinic synapses, producing this specific combination of effects. A selective agonist would only produce one class of effects, and an antagonist would block them.
- The persistent muscular symptoms are due to the overstimulation of which receptor?
Answer: Nicotinic Nₘ receptors at the neuromuscular junction.
Organophosphates inhibit acetylcholinesterase, causing an excess of acetylcholine (ACh) at all cholinergic synapses. Atropine is a muscarinic antagonist and reverses the effects of ACh at muscarinic receptors (resolving SLUD and bradycardia). However, it has no effect at nicotinic receptors. The muscle fasciculations and subsequent weakness are caused by excessive ACh stimulation of nicotinic Nₘ receptors at the neuromuscular junction, leading to a depolarizing blockade.
- A patient's eyes are examined after administration of eye drops. The pupils are dilated (mydriasis), and the ability to focus on near objects is impaired (cycloplegia). This effect could be produced by a drug that blocks which type of receptor in the eye?
Answer: Muscarinic M3 receptors on the pupillary constrictor and ciliary muscles.
When you encounter questions about pupillary dilation and cycloplegia, focus on the autonomic nervous system's control of eye muscles. The parasympathetic system normally keeps pupils constricted and enables near vision accommodation.
The symptoms described - mydriasis (pupil dilation) and cycloplegia (inability to focus on near objects) - indicate parasympathetic blockade. The parasympathetic nervous system controls two key eye muscles: the pupillary constrictor muscle (which normally constricts the pupil) and the ciliary muscle (which normally contracts to allow focusing on near objects). Both muscles are innervated by parasympathetic fibers that release acetylcholine, which binds to muscarinic M3 receptors.
Answer A is correct because blocking muscarinic M3 receptors prevents acetylcholine from activating these muscles, resulting in pupil dilation and loss of accommodation - exactly what's observed.
Answer B is wrong because blocking nicotinic receptors in the ciliary ganglion would prevent all parasympathetic transmission to the eye, but nicotinic receptors aren't the primary target of common mydriatic drugs like atropine.
Answer C is incorrect because stimulating (not blocking) alpha-1 receptors on the pupillary dilator muscle would cause mydriasis, but this wouldn't explain the cycloplegia since sympathetic stimulation doesn't significantly affect accommodation.
Answer D is wrong because extraocular muscles control eye movement, not pupil size or accommodation. These muscles aren't involved in the described symptoms.
Remember: Mydriasis plus cycloplegia = muscarinic blockade. This combination is classic for anticholinergic drugs used in eye exams.
- An experimental drug causes a rapid, marked increase in plasma epinephrine concentrations. This effect is abolished by pre-treatment with hexamethonium. The drug most likely acts as an agonist at which of the following receptors?
Answer: Nicotinic Nₙ receptors on adrenal chromaffin cells.
The adrenal medulla is a modified sympathetic ganglion. Preganglionic sympathetic neurons release acetylcholine (ACh) that acts on nicotinic Nₙ receptors on the adrenal chromaffin cells, stimulating the release of epinephrine and norepinephrine. Hexamethonium is a ganglionic blocking agent that antagonizes Nₙ receptors. Since hexamethonium abolishes the drug's effect, the drug must be an agonist at Nₙ receptors on the adrenal medulla.
- A patient with severe autonomic dysfunction is treated with midodrine, an alpha-1 adrenergic agonist, for orthostatic hypotension. To manage co-existing gastroparesis, they are also prescribed pyridostigmine, an acetylcholinesterase inhibitor. The patient then develops profound muscle weakness. Which of the following is the most likely explanation for the muscle weakness?
Answer: An excess of acetylcholine at the neuromuscular junction is causing a depolarizing block.
When you encounter questions about cholinesterase inhibitors and muscle weakness, think about acetylcholine's dual role at the neuromuscular junction - it's essential for muscle contraction, but too much can paradoxically cause weakness.
Pyridostigmine blocks acetylcholinesterase, the enzyme that breaks down acetylcholine. This leads to acetylcholine accumulation at the neuromuscular junction. Initially, this enhances muscle contraction, which is why pyridostigmine treats myasthenia gravis. However, excessive acetylcholine causes persistent depolarization of the muscle membrane, preventing it from repolarizing and becoming ready for the next contraction. This creates a "depolarizing block" - the muscle stays contracted and becomes weak and unresponsive, similar to what happens with succinylcholine overdose.
Choice A correctly identifies this mechanism - excess acetylcholine from pyridostigmine is causing depolarizing neuromuscular blockade. Choice B is incorrect because midodrine is an alpha-1 agonist that affects blood vessels, not nicotinic receptors at the neuromuscular junction. Choice C misunderstands the problem - muscarinic receptor changes in the gut wouldn't cause skeletal muscle weakness, and pyridostigmine increases cholinergic activity rather than causing receptor downregulation. Choice D is wrong because neither drug significantly blocks autonomic ganglia, and ganglionic blockade wouldn't directly cause skeletal muscle weakness.
Remember this key principle: cholinesterase inhibitors follow an inverted U-shaped dose-response curve. Moderate inhibition improves muscle function, but excessive inhibition causes the opposite effect through depolarizing block. Always consider dose-dependent effects when evaluating cholinergic drugs.
- A patient with myasthenia gravis is treated with pyridostigmine. The patient reports improved muscle strength but also complains of abdominal cramping and diarrhea. The therapeutic effect is mediated by nicotinic receptors, whereas the side effects are primarily mediated by which other type of receptor?
Answer: Muscarinic M3 receptors.
Pyridostigmine is an acetylcholinesterase inhibitor that increases acetylcholine (ACh) levels at all cholinergic synapses. In myasthenia gravis, the desired therapeutic effect is improved stimulation of nicotinic Nₘ receptors at the neuromuscular junction, increasing muscle strength. The common adverse effects, such as cramping and diarrhea, are due to excessive stimulation of muscarinic (primarily M3) receptors in the smooth muscle of the gastrointestinal tract.
- Administration of a muscarinic agonist, such as pilocarpine, can induce diaphoresis (sweating). This physiological response is considered an exception in autonomic pharmacology because it is mediated by:
Answer: sympathetic postganglionic neurons that release acetylcholine.
Most eccrine sweat glands are innervated by the sympathetic nervous system. In a notable exception to the rule that sympathetic postganglionic neurons release norepinephrine, the neurons innervating these sweat glands are cholinergic. They release acetylcholine (ACh), which acts on muscarinic (M3) receptors on the glands to stimulate sweat production. Therefore, a muscarinic agonist mimics this sympathetic cholinergic pathway.
- An anesthetized experimental animal is pre-treated with a high dose of atropine. Subsequently, a large intravenous bolus of acetylcholine is administered. Which of the following cardiovascular responses would be expected?
Answer: A significant increase in blood pressure and heart rate.
Atropine, a muscarinic antagonist, blocks the M2 and M3 receptor-mediated cardiovascular effects of acetylcholine (vasodilation, bradycardia). With the muscarinic effects blocked, the high dose of acetylcholine stimulates nicotinic receptors. This includes Nₙ receptors in sympathetic ganglia and the adrenal medulla, triggering the release of norepinephrine and epinephrine. This catecholamine release leads to vasoconstriction (increased blood pressure) and tachycardia (increased heart rate), a phenomenon known as 'atropine reversal'.
- A patient is administered an autonomic drug and subsequently develops significant orthostatic hypotension, urinary retention, and anhidrosis. Skeletal muscle strength remains normal. These findings are most consistent with the administration of an antagonist for which receptor subtype?
Answer: Nicotinic Nₙ receptors.
This combination of symptoms points to a broad blockade of the autonomic nervous system at the ganglionic level. Nₙ receptor antagonists block both sympathetic and parasympathetic outflow. Sympathetic blockade causes loss of vascular tone (orthostatic hypotension) and blocks sweating (anhidrosis). Parasympathetic blockade causes urinary retention. Critically, skeletal muscle strength is normal because Nₘ receptors at the neuromuscular junction are unaffected.
- Both botulinum toxin and d-tubocurarine cause skeletal muscle paralysis. A key difference is that d-tubocurarine's effects can be partially overcome by an acetylcholinesterase inhibitor (e.g., neostigmine), whereas the effects of botulinum toxin cannot. This is because d-tubocurarine is a:
Answer: competitive antagonist at postsynaptic Nₘ receptors, while botulinum toxin prevents presynaptic ACh release.
When you encounter questions about neuromuscular blocking agents, focus on the fundamental difference between competitive and non-competitive antagonism, and whether the drug acts presynaptically or postsynaptically.
D-tubocurarine is a competitive antagonist that binds reversibly to postsynaptic nicotinic receptors (Nₘ) at the neuromuscular junction. Because it competes with acetylcholine (ACh) for the same binding site, increasing ACh concentration can overcome the blockade. Acetylcholinesterase inhibitors like neostigmine work by preventing ACh breakdown, thereby increasing synaptic ACh levels and allowing it to outcompete d-tubocurarine for receptor binding.
Botulinum toxin works entirely differently—it cleaves SNARE proteins in presynaptic nerve terminals, preventing ACh vesicles from fusing with the membrane and releasing their contents. No amount of ACh can be released, so increasing ACh levels with neostigmine is futile.
Choice A reverses the mechanisms—botulinum toxin is the presynaptic inhibitor, not d-tubocurarine. Choice B incorrectly describes d-tubocurarine as a depolarizing agonist (that's succinylcholine) and wrongly states botulinum toxin degrades ACh (it prevents ACh release). Choice C misclassifies d-tubocurarine as non-competitive and botulinum toxin as a depolarizing blocker.
Remember this pattern: competitive antagonists can be overcome by increasing the natural ligand concentration, while drugs that prevent neurotransmitter release cannot. This distinction frequently appears on pharmacology exams when comparing different classes of neuromuscular blocking agents.
- A patient is administered a drug that acts as a selective antagonist at Nₙ receptors. Which of the following clinical effects would be most prominent and helps differentiate this drug's primary mechanism from that of a muscarinic antagonist like atropine?
Answer: Orthostatic hypotension due to blockade of sympathetic reflexes.
Nₙ receptor antagonists (ganglionic blockers) block neurotransmission in both sympathetic and parasympathetic ganglia. The most prominent effect on blood vessels, which are primarily under sympathetic tone, is vasodilation leading to orthostatic hypotension. This effect is not a primary feature of muscarinic antagonists. Options A and C are effects of muscarinic antagonists. Option D would result from blockade of Nₘ receptors at the neuromuscular junction.
- A patient with postoperative urinary retention is to be treated with a cholinergic agent. The physician wants to directly stimulate bladder smooth muscle with minimal effects on autonomic ganglia or the neuromuscular junction. Which drug is most appropriate?
Answer: Bethanechol
The detrusor muscle of the bladder is contracted via parasympathetic stimulation of muscarinic M3 receptors. Bethanechol is a direct-acting muscarinic agonist with relative selectivity for the bladder and GI tract. It has negligible effects on nicotinic receptors. In contrast, neostigmine (an AChE inhibitor), nicotine, and succinylcholine (nicotinic agonists) would all have significant effects at nicotinic receptors in ganglia and the neuromuscular junction, which is undesirable in this case.
- A research lab compares two novel neuromuscular blocking agents. Drug A causes complete flaccid paralysis at a dose that has no effect on blood pressure. Drug B causes profound hypotension at a dose that only produces partial muscle weakness. Which of the following best characterizes these two drugs?
Answer: Drug A is a selective Nₘ antagonist; Drug B is a non-selective nicotinic antagonist.
The neuromuscular junction contains Nₘ receptors, and blockade causes paralysis. Autonomic ganglia contain Nₙ receptors, and blockade causes hypotension. Drug A is selective for Nₘ receptors because it causes paralysis without affecting blood pressure. Drug B acts on both receptor subtypes, causing both hypotension (Nₙ blockade) and muscle weakness (Nₘ blockade), making it a non-selective nicotinic antagonist.
